Company (Symbol)* |
Product |
Description |
Indication |
Status (Date)** |
CANCER | ||||
CEL-SCI Corp. (AMEX: HIV) |
Multikine | Natural mixture of human cytokines, including interleukin-2 |
Advanced head and neck cancer | Presented results of Phase II trial in Poland and the Czech Republic at the Biotechnology Industry Organization's CEO & Investor Conference in New York (2/15) |
Genzyme General (division of Genzyme Corp; GENZ) and Biobras SA (Brazil) | Thyrogen (FDA-approved) | Recombinant human thyroid stimulating hormone |
Follow-up screening for patients who have been treated for thyroid cancer | Cleared for marketing in Brazil (2/2) |
Medarex Inc.(MEDX), Immuno-Designed Molecules SA* and ImmunoDesigned Molecules Inc.* |
MDX-210 |
Bispecific antibody that targets HER2 receptor |
Ovarian cancer |
Received European regulatory approval to initiate Phase III trial of MDX-210 in combination with IDM's Monocyte-derived Activated Killer (MAK) cell technology (2/14) |
SuperGen Inc. (SUPG) |
Rubitecan; oral chemotherapy compound in the camptothecin class | Pancreatic cancer |
IND approved in Canada (2/4) |
|
CENTRAL NERVOUS SYSTEM | ||||
Active Biotech AB (Sweden; ACTIB) | SAIK-MS |
Orally active immune response regulator | Multiple sclerosis | Reported results in initial portion of Phase I trial; Swedish medical products agency approved a more extensive study (2/12) |
SkyePharma plc (UK; SKYE) |
DepoMorphine | Sustained-release, encapsulated morphine sulfate (uses Depo-Foam, lipid-based drug delivery) |
Hip replacement surgery |
Announced Phase II trial results in Canada (2/22) |
DIABETES | ||||
Generex Biotechnology Corp. (OTC BB: GNBT) | Oralin |
Oral insulin; administered as a fine spray into the oral cavity using a lightweight handheld aerosol applicator | Diabetes |
Initiated trials in Engand comparing Oralin to subcutaneous insulin injection and placebo (3/9) |
INFECTION | ||||
Advanced Viral Research Corp. (OTC BB: ADVR) |
Substance R | Non-toxic peptide nucleic acid immuno-modulator |
Viral infection | Received approval for Phase I trials in Argentina (2/18) |
Bio-Technology General Corp. (BTGC) |
Bio-Hep-B | Recombinant hepatitis B vaccine that integrates the S, pre-S1 and pre-S2 surface proteins of the virus | Prevention of hepatitis B infection | Cleared for marketing in Israel (2/14) |
Enzon Inc. (ENZN) and Schering Plough Corp. (NYSE:SGP) |
Peg-Intron |
Long-acting dosage form of Schering's Intron A (recombinant interferon alfa-2b) conjugated to polyethylene glycol | Hepatitis C infection in adults | European Agency for the Evaluation of Medicinal Products issued recommended approval (2/22) |
The Immune Response Corp. (IMNR) and Agouron Pharmaceuticals Inc. (subsidiary of Warner-Lambert Co. [NYSE: WLA]) |
Remune | Envelope-depleted, inactivated AIDS virus (emulsified with adjuvant) |
HIV infection |
Submitted Phase II trial data to the Thai Ministry of Health (2/23) |
The Liposome Company Inc. (LIPO) | Abelcet |
Complex of amphotericin B with two phospholipids |
Invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B |
Cleared for marketing in Lebanon (2/17) |
PathoGenesis Corp. (PGNS) |
TOBI |
Tobramycin solution for inhalation and AMRAD Pharmaceuticals Ptd. Ltd. (Australia) | Management of cystic fibrosis patients with Pseudomonas aeruginosa infections |
Cleared for marketing in Australia (2/23) |
MISCELLANEOUS | ||||
Centocor Inc. and Schering-Plough Corp. (NYSE:SGP) |
Remicade (FDA- approved) | Infliximab; chimeric monoclonal antibody to tumor necrosis factor alpha |
Rheumatoid arthritis that has inadequately responded to dissease-modifying drugs; combination therapy with methotrexate |
Committee for Proprietary Medicinal Products of the European Agency for the Evaluation of Medicinal Products recommended approval (2/23) |
Genzyme General (GENZ) and GelTex Pharmaceuticals Inc. (GELX) | Renagel Capsules (FDA-approved) |
Non-absorbed polymer-based compound that binds to and eliminates target substances from the intestinal tract |
Hyperphosphatemia | Cleared for marketing in the 15 member states of the European Union (2/3) |
Immunex Corp. and Wyeth-Ayerst Pharmaceuticals (the pharmaceutical division of American Home Products Corp. [NYSE:AHP]) |
Enbrel (FDA-approved) | Entanercept; recombinant, soluble T75 tumor necrosis factor receptor (TNFr) linked to the Fc portion of human IgG1 |
Adult rheumatoid arthritis that inadequately responds to disease-modifying drugs |
Cleared for marketing in 15 European Union countries by the European Medicines Evaluation Agency (2/7) |
Notes: | ||||
* Indicates a privately held company | ||||
** The dates listed indicate the issue dates of press releases, and are not necessarily the dates on which stated events took place. | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SSE = Swedish Stock Exchange; TSE = Toronto Stock Exchange |
||||
ND = Not disclosed | ||||
IND = Investigational new drug application | ||||
